title: Serum anti-Müllerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome.
abstract: OBJECTIVE
  To describe changes of anti-Müllerian hormone (AMH) and inhibin B during low-dose gonadotropin ovulation induction (OI) treatment in women with polycystic ovary syndrome (PCOS), and thus disturbed selection of the dominant follicle.
  
  
  METHODS
  Observational study.
  
  
  METHODS
  A referral fertility clinic.
  
  
  METHODS
  Women with PCOS (n = 48) and normo-ovulatory women (n = 23).
  
  
  METHODS
  Serum AMH, inhibin B, FSH, and E(2) concentrations were measured at start of stimulation, on the day of follicle selection, and at administration of hCG during OI cycles and were compared with concentration measured during the normal menstrual cycle.
  
  
  RESULTS
  Development of a single dominant follicle was observed in 92% of all OI cycles, reflected by similar E(2) concentrations compared with those in spontaneous cycles. AMH concentrations were constant during low-dose ovarian stimulation. Inhibin B concentrations remained elevated in patients with PCOS, suggesting prolonged survival of small antral follicles, whereas in controls inhibin B concentrations declined during the late follicular phase.
  
  
  CONCLUSIONS
  The lack of change in AMH and inhibin B concentrations suggest that follicle dynamics during low-dose stimulation seem different from those during controlled ovarian hyperstimulation. In addition, constant AMH and inhibin B levels suggest that neither AMH nor inhibin B is an accurate marker of ovarian response after low-dose gonadotropin OI in patients with PCOS.
authors: Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Erasmus MC, Rotterdam, the Netherlands. s.liefong@erasmusmc.nl
authors: Sharon
authors: S
authors: Lie Fong
authors: Izaäk
authors: I
authors: Schipper
authors: Frank H
authors: FH
authors: de Jong
authors: Axel P N
authors: AP
authors: Themmen
authors: Jenny A
authors: JA
authors: Visser
authors: Joop S E
authors: JS
authors: Laven
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D054304:Anti-Mullerian Hormone / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D004958:Estradiol / Q000097:blood; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D043373:Follicle Stimulating Hormone, Human / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D007265:Inhibins / Q000097:blood*; D009426:Netherlands; D010060:Ovulation / Q000187:drug effects*; D010062:Ovulation Induction; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D015415:Biomarkers; D005300:Fertility Agents, Female; D043373:Follicle Stimulating Hormone, Human; D011994:Recombinant Proteins; C422364:inhibin B; D004958:Estradiol; D007265:Inhibins; D054304:Anti-Mullerian Hormone